Metformin: an Old Therapy that Deserves a New Indication for the Treatment of Obesity
Authors:
- 18 February 2016
- journal article
- review article
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 18 (4) , 1-8
Abstract
Metformin is not currently used for weight loss or diabetes prevention because it lacks an FDA indication for obesity and/or pre-diabetes treatment. Based on the evidence, metformin has been shown to decrease the incidence of type 2 diabetes, and compares favorably to other weight-loss medications in terms of efficacy as well as safety. Thus, metformin should be considered for a treatment indication in patients with these conditions.Keywords
This publication has 58 references indexed in Scilit:
- Metformin for Weight Loss and Metabolic Control in Overweight Outpatients With Schizophrenia and Schizoaffective DisorderAmerican Journal of Psychiatry, 2013
- Metformin: an old but still the best treatment for type 2 diabetesDiabetology & Metabolic Syndrome, 2013
- Metformin modifies the exercise training effects on risk factors for cardiovascular disease in impaired glucose tolerant adultsObesity, 2013
- The 10-Year Cost-Effectiveness of Lifestyle Intervention or Metformin for Diabetes PreventionDiabetes Care, 2012
- Long-Term Safety, Tolerability, and Weight Loss Associated With Metformin in the Diabetes Prevention Program Outcomes StudyDiabetes Care, 2012
- Effect of metformin on cardiovascular events and mortality: a meta‐analysis of randomized clinical trialsDiabetes, Obesity and Metabolism, 2011
- Metformin for Atypical Antipsychotic-Induced Weight Gain and Glucose Metabolism DysregulationCNS Drugs, 2010
- 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes StudyThe Lancet, 2009
- Effects of Intensive Glucose Lowering in Type 2 DiabetesNew England Journal of Medicine, 2008
- Metabolic and Hemodynamic Effects of Metformin and Glibenclamide in Normotensive NIDDM PatientsDiabetes Care, 1993